-
Sector Analysis
Missiles and Missile Defense Systems Market Size and Trend Analysis by Segments, Programs, Competitive Landscape and Forecast to 2033
Missiles and Missile Defense Systems Market Overview The global missiles and missile defense systems (MMDS) market is valued at $45.2 billion in 2023 and will grow at a compound annual growth rate (CAGR) of more than 4% during 2023-2033. The MMDS market will be driven by the rise in air defense modernization and advanced precision strike missile procurement programs by key defense spending countries, such as the US, Russia, China, India, Poland, and the UK, among others. The increased focus...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Resiniferatoxin in Osteoarthritis Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Resiniferatoxin in Osteoarthritis PainDrug Details:Resiniferatoxin (RTX) is under development for the treatment of chronic osteoarthritis pain,...
-
Company Insights
Raytheon Technologies – Digital Transformation Strategies
Raytheon Technologies Corp (RTX) Digital Transformation Strategies Report Overview Raytheon Technologies Corp (RTX) has been focusing on using artificial intelligence, machine learning, cloud, big data, and 3D printing to digitally transform its operations. The annual ICT spending of RTX was estimated at $5.4 billion for 2022. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. RTX, formerly United Technologies Corp, is a provider of technology products and services to the aerospace...
-
Thematic Analysis
New![]()
Space Economy – Thematic Intelligence
Space launches used to be rare, memorable events of global significance, such as the Apollo 11 mission that landed on the Moon in 1969. In the future, the launch of rockets capable of taking satellites into orbit will become much more commonplace. SpaceX alone will launch around 90 rockets in 2023. In 2022, the space economy was worth approximately $450 billion. Market estimates suggest it will be worth between $760 billion and $1 trillion by 2030, growing at a compound...
-
Thematic Analysis
![]()
Artificial Intelligence (AI) in Defense – Thematic Intelligence
AI in Defense Thematic Overview Around the world, many companies and militaries are investing in AI to augment and enhance their current capabilities. However, rapid progress in AI has made it a key battleground technology for countries like the US and China, who have each enacted policies to limit the other's access to materials and technology associated with AI research and development (R&D). However, AI integration presents many ethical challenges across the defense sector ranging from humanitarian to regulatory concerns...
-
Thematic Analysis
New![]()
Hydrogen Aircraft – Thematic Intelligence
Hydrogen Aircraft Thematic Report Overview Hydrogen aircraft offer sustainable alternatives for air travel. Hydrogen has significant potential as it can be produced in a way that is carbon-free and when used as a fuel only produces water – making it appealing for states and companies attempting to reduce their climate impact. However, the development of the aircraft faces major challenges in terms of technology as well as infrastructure. Advancements need to be made to facilitate the use of hydrogen in...
-
Sector Analysis
Missiles and Missile Defense Systems Market Analysis and Forecast to 2033 (Report Bundle)
The Global Missiles and Missile Defense Systems Market 2023–33 dataset provides the market size forecast and the estimated Compound Annual Growth Rate (CAGR) for the next ten years. The report covers industry analysis, including the key market drivers, trends, emerging technologies, and major challenges faced by industry participants. It also offers insights regarding key factors and government programs that are expected to influence the demand for the missiles and missile defense systems market over the forecast period. The quantitative report...
-
Company Profile
![]()
Rubius Therapeutics Inc – Company Profile
Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company. It focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company's RCT pipeline products comprise of RTX-240, RTX-321 aAPC, RTX-224, RTX-aAPC, and RTX-T1D. Its products under development are intended for the treatment of human papillomavirus 16-positive cancers, non-small cell lung cancer, type 1 diabetes, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. The company also offers...
Add to Basket -
Product Insights
![]()
Net Present Value Model: RTX-321
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RTX-321 Drug Details RTX-321 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – RTX-321
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RTX-321 Drug Details RTX-321 is under development for the treatment of HPV-16 associated solid...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – RTXGRT-7039
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RTXGRT-7039 Drug Details RTX-GRT7039 is under development for the treatment of pain associated with...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – resiniferatoxin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry resiniferatoxin Drug Details Resiniferatoxin (RTX) is under development for the treatment of opiate refractory...
-
Product Insights
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteoarthritis Pain Pipeline Drugs Market Overview Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape. Osteoarthritis Pain Pipeline Drugs Market is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint...
-
Product Insights
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe...
-
Product Insights
Immunosuppressant Therapeutic Drug Monitoring Tests – Medical Devices Pipeline Assessment, 2020
Immunosuppressant Therapeutic Drug Monitoring are the reagents used for the detection of immunosuppressant concentration in human body are covered under immunosuppressant TDM surgical devices that are used to make a tiny incision in the areas to be operated. GlobalData's Medical Devices sector report, “Immunosuppressant Therapeutic Drug Monitoring Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Immunosuppressant Therapeutic Drug Monitoring Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical...
-
Company Insights
COVID-19 Impact on Raytheon Technologies Corp
Raytheon Technologies Corp (RTX), formerly United Technologies Corp, is a provider of technology products and services to the aerospace and defense industries. The company offers commercial, general aviation and military aircraft engines, engine control systems, power generation management and distribution systems, and flight systems. It also offers air dominance, command and control, communications and navigation, cybersecurity, decision superiority, air warfare, counter UAS, hypersonics, missile defense, naval warfare, land warfare and space solutions. The company provides fleet management services, and aftermarket...
-
Product Insights
Cancer Pain Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, H2, 2017" provides an overview of Cancer Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Cancer Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Analyst Opinions
International Wholesale Carriers – Ecosystem Players’ Evolution: Mergers & Acquisitions, Open Initiatives, and Potential New Entrants in the Digital Transformation Era
"International Wholesale Carriers - Ecosystem Players’ Evolution: Mergers & Acquisitions, Open Initiatives, and Potential New Entrants in the Digital Transformation Era", a thematic research report by GlobalData, lays out key strategies wholesale providers and major Internet players have been harnessing to meet the changing requirements of the wholesale market in the digital transformation era. Global wholesale carriers are under pressure to accelerate the rollout of new services, reduce exposure to voice and migrate to new agile business models. Alongside traditional...
-
Consumer Insights
KOL Perspectives: Rituximab Use in Lupus
This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.